Several clinical trials targeting antigens such as C-type lectin-like molecule-1 (CLL-1), CD33, and CD123 have shown promise in AML and may hold potential for application in MPNs, particularly for patients with accelerated disease or those who have progressed to post-MPN AML [56]. Here, CD33 is linked to myeloproliferative disorder.